On the 7th of December 2011 there was the opening ceremony of
the research and development center of the GEROPHARM company in a
special economic zone of technology-innovative type (SEZ T&I TYPE).
Saint Petersburg governor Georgy Poltavchenko, chairman of St.
Petersburg's Committee for Economic Development, Industrial Policy and
Trade (CEDIPT) Yevgeny Yelin, GEROPHARM CEO, Peter Rodionov, the CEO of
JSC “Special Economic Zones” Oleg Kostin, rector of St. Petersburg
Chemical and Pharmaceutical Academy Igor Narkevitch and also numerous
representatives of authorities, science, business and MSM were among the
guests who took part in the opening ceremony. The governor saw over the
laboratories of the R&D center along with holding a conference on
Saint Petersburg Pharmaceutical cluster development.
The new R&D center of the GEROPHARM company will operate a full
cycle complex pharmaceutical development consisting of synthesis and
screening of new molecules, development, analysis and innovation in new
drugs and medical products (diagnostic systems) production. One of the
separate lines of activities is carrying-out of wide range of analyses
aimed at clinical development support.
“This modern R&D center became one of the first centers in Saint
Petersburg opened within a matter of developing pharmaceutical cluster”,
— mentioned the chairman of CEDIPT Yevgeny Yelin.
The R&D center construction investments exceed 120 million
roubles. The amount of new workplaces in the laboratories of the R&D
center is more than 50. The R&D center consists of the synthetic
and analytical laboratories along with the development laboratory for
finished dosage form. All the divisions are modern equipped, and the
company expects the innovation of the newest Laboratory Information
Management System (LIMS) in the near future.
CJSC Pharm-Holding, an affiliated company of GEROPHARM, is liable for
the R&D direction’s growth as well as the construction of a new
laboratory complex. Since that moment all the company’s developments
will be carried out on the basis of the new R&D center.
Today, all the research officers of Pharm-Holding work at the
invention of the products aimed at the treatment of socially significant
diseases, diseases in neurology, ophthalmology, urology, gynecology,
endocrinology, hepatology and also serious vascular abnormalities. Along
with the development of pharmaceutical products, the company carries
out the development of medical products (diagnostic systems) allowing
diagnosing the early stages of diseases and monitoring the efficiency of
Among the projects of the most priority there is also the development
of an innovative genetically engineered product on the basis of
C-Peptide (treatment of complications of diabetes), analogue insulin
(diabetes treatment) and fractionated heparin (treatment of thrombosis
and thrombembolias, strokes and infarcts).
Scientific researches in the field of C-Peptide (fragments of the
proinsulin molecule) are an innovative direction of the modern
pharmaceuticals industry development. From the middle of the 90’s there
is an active research of C-Peptide’s functions and possible
therapeutical role this product plays in the world. And now it is
scientifically proved that C-Peptide sharply slows down and prevents
development of the most serious complications of diabetes.
The company’s project on research and development activity concerning
an innovative product on the basis of C-Peptide parcticipates in FTP
“Development of the Pharmaceutical and Medical Industry of the Russian
Federation until 2020 and beyond.” The field of applications of the
developing pharmaceutical product is pathogen control of vascular
complications of diabetes’ emergency and prevention of their
progression. In 2011 the company has finished an important stage of its
researches. It has developed the technology of reception of the product
on the basis of C-Peptide. At the present time Pharm-Holding’s
scientists continue the researches on searching of the most optimal
The company’s workings out in the field of analogue insulin and
fractionated heparin have a top-priority meaning of prime importance for
the Russian pharmaceutics industry since the domestic pharmaceutical
production of these pharmaceutical products is absent in the country at
the moment. The products presented on the market are the patented
products of the foreign companies. In addition, according to the data
from “Pharmexpert” Market Research Centre (MRC), in 2010 the market
volumes of analogue insulin and fractionated heparin in Russia amounted
to USD 157 and 86 million dollars, respectively.
The company intends to submit documents for registration of analogue
insulin and fractionated heparin in 2012. The release of the developing
products will be adjusted on Geropharm‘s production areas, including the
factory which is now being built in the town of Pushkin, within a
matter of developing pharmaceutical cluster.
According to the words of Georgy Poltavchenko, the residents of Saint
Petersburg Pharmaceutical cluster will be able to take part in municipal
order competitions in the next year already. “I am confident that they
will give both quality and price which the town will be interested in,
and that means the products will get to St. Petersburg’s drugstores,
hospitals and clinics”, – said Georgy Poltavchenko.
“The creation of its own R&D center specializing on carrying out of full cycle complex pharmaceutical development will allow the company to strengthen the direction on creation and release of new socially important pharmaceutical products (as well as innovative and improved generic ones, prioritized for import substitution), — commented Peter Rodionov, the GEROPHARM CEO. — The realization of the present project will accelerate and make the introduction process of scientific research results in industrial production as effective as possible”.